Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

DNA Script Wins ARPA-H Award to Advance DNA Manufacturing

Published

on

DNA Script, in collaboration with GE HealthCare, has been awarded up to $26 million in funding for a four-year initiative from the Advanced Research Projects Agency for Health (ARPA-H). The award will support the advancement of the Flexible Automation for Scalable Health (FLASH) program, focused on the development of scalable cell-free DNA bioproduction capabilities and powered in part by DNA Script’s enzymatic DNA synthesis (EDS) technology and SYNTAX® platform.

Led by GE HealthCare, the FLASH program aims to develop a modular, automated platform for the rapid, distributed manufacturing of high-fidelity DNA to support research and potential future applications in personalized medicines, vaccines, and other genetic health technologies. DNA Script’s EDS technology supports this goal by enabling faster and more flexible DNA manufacturing workflows.

DNA Script, which is contributing its EDS technology and acting as the technical solution integrator for the project, says the company has adapted its solution to incorporate GE HealthCare’s proprietary DNA scaling technology, complementing DNA Script’s EDS technology, with the goal of eventually deploying the integrated platform across U.S. medical research centers, universities, and federal agencies.

“ARPA-H solutions are designed to address hard problems with bold, practical approaches,” says John Schiel, program manager, ARPA-H. “Projects like FLASH exemplify how scalable, platform-based technologies can transform the way health solutions are developed, produced, and delivered.”

“Our enzymatic DNA synthesis platform is ideally suited for the on-demand manufacturing model FLASH is pioneering,” adds Marc Montserrat, CEO, DNA Script. “Collaborating with GE HealthCare on an ARPA-H program of this scale shortens the path from research bench to patient bedside for next-generation therapies, personalized vaccines, and the broader genetic-medicine pipeline.”

“As personalized and time-sensitive genetic medicines continue to advance, there is a growing need for manufacturing approaches that are faster, more flexible, and more accessible,” notes John Nelson, senior bioscience principal and FLASH program lead, GE HealthCare’s Technology and Innovation Center. “Our vision for the FLASH program is to develop new DNA-based medicines on demand quickly, safely, and at scale.”

The FLASH program has been designed to bring together expertise in automation, DNA synthesis and scaling, purification, and genomic validation.

 

 

The post DNA Script Wins ARPA-H Award to Advance DNA Manufacturing appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read